Fundly.ai has raised $4 million in a fresh equity funding round. The round was led by Accel and Multiply Ventures. The current investment arrives amid robust investment in technology aimed at transforming the Indian pharmaceutical supply chain. In addition to the lead venture capitalists, the round was also backed by former executive director at RBL Bank Rajeev Ahuja along with other notable angel investors.

Strategic capital utilization

Fundly.ai extended its financial capabilities by taking out approximately $0.9 million in venture debt in addition to financing the initial round of equity. The blend of equity and venture debt capital provides the firm with adequate liquidity to facilitate its strategic undertakings.

The accomplishment of this financial milestone is an indication of continued confidence among the investors in the future business prospects of the firm. The funds obtained through the acquisition would be used strategically to strengthen Fundly.ai’s overall market presence and core technology ecosystem. 

The fresh funding, combined with the increased venture debt, will be leveraged by the company to grow its full range of digital commerce, payments, and credit products for India’s pharma supply chain. The expansion of these operational pillars will help Fundly.ai make significant strides toward eliminating major inefficiencies and key digital gaps present in traditional pharmaceutical distribution channels.

The investment will help the company’s expansion efforts as it scales its digital infrastructure to cater to more healthcare merchants, distributors, and chain stakeholders from different geographies in India. Fundly.ai’s strategy of pairing digital commerce with specialized financial products positions it to expand its reach in the nation’s massive and intricate pharmaceutical logistics and distribution system. 

Financial growth and core offerings

Fundly.ai was founded in 2021 by Amit Chawla and Shreeram Ramanathan. The company’s early capitalization was mostly as a dedicated supply-chain financing platform, specifically engineered to meet the unique needs of the pharmaceutical sector. 

In response to changing market needs, the startup has expanded its vision from the early funding model to provide a streamlined and comprehensive package of services to the industry.

Since its launch, Fundly.ai has been methodically scaling its business model across three core functional areas of B2B commerce: payment and settlement infrastructure, and embedded credit solutions. 

With this multifaceted approach, Fundly.ai wants to equip pharma retailers and distributors with the ability to manage daily operations smoothly. The startup integrates procurement, payment processes, and working capital management within one technology platform, giving business operators the ability to handle their end-to-end supply chain activities more efficiently and conveniently.

The latest $4 million investment is a pivotal moment on Fundly.ai’s financial path. The company raised a $3 million seed funding round in 2023. The seed funding round was led by Accel. The round saw participation from Multiply Ventures and some angel investors. 

Its ongoing involvement in the current round suggests ongoing alignment with the management team and early-stage investors. The persistent institutional investment from funders such as Accel and Multiply Ventures is a testament to the ongoing trust in Fundly.ai’s ability to reach its vision for the business. 

The platform secured an additional equity cash contribution of $4 million and a venture debt contribution of $0.9 million, further solidifying its presence as an emerging tech-enabled stakeholder in the Indian Pharmaceutical Supply Chain ecosystem.

Founders Amit Chawla and Shreeram Ramanathan have kept the company resolute in its mission of making procurement and payments for retailers and distributors in India easy and working capital simple with its technology platform. 

With a $3 million seed round of funding, Fundly.ai is now on track to continue with expansions and accelerate further digital transformation in the country’s pharma distribution market.

Conclusion

The $4 million raised in funding and around $0.9 million in venture debt has represented a significant milestone for Fundly.ai as a B2B pharma distributor. The investment comes from current active investors Accel and Multiply Ventures, alongside RAJAJEET AHUJA, a former Executive Director of RBL Bank, as well as other angel investors, indicating strong endorsement of the platform.

As a supply-chain financing platform, Fundly.ai seeks to further expand its digital commerce, payment infrastructure, and embedded credit capability throughout the Indian pharmaceutical supply chain.